HealthPolitics
STAT+: Lawmakers want U.S. biotech to outcompete China
Publication: STAT
Author: Meghana Keshavan
Source published: 19/11/2026, 17:04:46 UTC
Briefing created: 19/11/2026, 17:08:07 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 17:06:24 UTC.
Briefings
A biotech newsletter article reports that Merck is recruiting AI firm Isomorphic Labs to analyze its own oncology data for small molecule targets. The article notes Merck's strategic importance of its current oncology target and mentions a trove of wet lab data from Merck's own work. The text explicitly states that the newsletter is bringing in Isomorphic to see if their AI models can find promising targets faster using Merck's data.
Key points
- Merck is recruiting Isomorphic Labs to analyze its own oncology data for small molecule targets.
- The article notes Merck's strategic importance of its current oncology target and mentions a trove of wet lab data from Merck's own work.
Context
STAT+ newsletter provides biotech insights on regulatory and scientific developments, specifically mentioning a recruitment of AI firms to analyze proprietary data for drug discovery.
Limitations
The evidence is a short newsletter excerpt with no dates, author names, or specific numbers provided. The article does not state whether the AI models are ready to use the data or if the recruitment is confirmed.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 17:08:07 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifxee2dajad3ykuo6l5ymdcy6f6rtw5i5uxoiofes2famdgsotr3u